Filament Health, acquired by Red Light Holland, will provide its patented botanical psilocybin drug candidate PEX010 to the University of California, San Francisco (UCSF) for a clinical trial. The study will investigate the effects of a single dose of psilocybin on brain activity, neuroinflammation, and preclinical Alzheimer's disease markers in healthy older adults. This collaboration highlights the growing demand for pharmaceutical-grade natural psilocybin in academic research and reinforces Filament's role as a leading supplier in the psychedelic drug development sector. The UCSF trial is independently conducted, aiming to explore subtle brain changes related to aging and neurodegeneration using advanced imaging and biomarker analysis.
